Denali Therapeutics Inc. Annual Share-based Payment Arrangement, Expense in USD from 2016 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Denali Therapeutics Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2016 to 2023.
  • Denali Therapeutics Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $24.9M, a 9.47% decline year-over-year.
  • Denali Therapeutics Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $104M, a 3.27% decline year-over-year.
  • Denali Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2023 was $108M, a 8.27% increase from 2022.
  • Denali Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2022 was $99.8M, a 17.1% increase from 2021.
  • Denali Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2021 was $85.2M, a 69.3% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $108M +$8.26M +8.27% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-28
2022 $99.8M +$14.6M +17.1% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-28
2021 $85.2M +$34.9M +69.3% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-28
2020 $50.4M +$12M +31.2% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-27
2019 $38.4M +$19.6M +104% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-28
2018 $18.8M +$14.4M +326% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-26
2017 $4.41M +$1.46M +49.4% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-27
2016 $2.95M Jan 1, 2016 Dec 31, 2016 10-K 2019-03-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.